AAPG: SEC Form 6-K filed by Ascentage Pharma Group International
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for AAPG
Across the 28 sessions after earlier AAPG headlines, the stock closed higher 11 times and lower 16 times, with a median move of 2.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | AAPG | SPY |
|---|---|---|---|
| Oct 21, 2026 | Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL | +2.6% | +0.5% |
| Oct 14, 2026 | Citigroup initiated coverage on Ascentage Pharma with a new price target | -1.4% | -1.1% |
| Oct 13, 2026 | Citizens initiated coverage on Ascentage Pharma with a new price target | -1.6% | -0.0% |
| Sep 2, 2026 | Ascentage Pharma to Participate in Four Upcoming Investor Conferences | +3.6% | +0.4% |
| Aug 20, 2026 | Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates | -3.9% | -0.8% |
| Aug 13, 2026 | Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit | +0.2% | +0.7% |
Quantisnow market dataNASDAQ
AAPG
Ascentage Pharma Group International
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2025
Get push alerts for AAPG
Full AAPG profile on Quantisnow Follow AAPG and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time